Aktuellt
SENASTE
Redeye comments on Sprint Bioscience's Q3 2021 report, which was in line with our expectations. In our view, the third-quarter highlight constituted Sprint licensing its Vps34 project to Deciphera Pharmaceuticals. Sprint is currently marketing two other projects to potential partners, meaning we may see an additional licensing deal during the coming quarters. We believe the company has built momentum to continue to deliver positive newsflow as we advance.
LÄS MER
